Downstream targets of growth factor and oestrogen signalling and endocrine resistance: The potential roles of c-Myc, cyclin D1 and cyclin E

Endocrine-Related Cancer

Volumn 12, Issue SUPPL. 1, 2005, Pages

  Butt, Alison J ^a,b   McNeil, Catriona M ^a,b   Musgrove, Elizabeth A ^a,b   Sutherland, Robert L ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CYCLIN D1; CYCLIN E; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; GROWTH FACTOR; TAMOXIFEN;

BREAST CANCER; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONFERENCE PAPER; DISEASE COURSE; ESTROGEN ACTIVITY; HUMAN; MITOGENICITY; ONCOGENE C MYC; PROTEIN EXPRESSION; UPREGULATION;

BREAST NEOPLASMS; CYCLIN D1; CYCLIN E; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; GROWTH SUBSTANCES; HUMANS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 25844515780     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00993     Document Type: Conference Paper

References (122)

1. Akli S, Zheng P-J, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S & Keyomarsi K 2004 Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Research 64 3198-3208.
2. Al-Kuraya K, Schrami P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spcihtin H, Maurer R, Mirlacher M, Kochli O, Zuber M, Dieterich H, Mross F, Wilber K, Simon R & Sauter G 2004 Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Research 64 8534-8540.
3. Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M, Beato M, Sica V, Bresciani F & Weisz A 1996 17beta-Estradiol induces cyclin D1 gene transcription, p36Dl-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 12 2315-2324.
4. Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene 18 3085-3097.
5. WAF1 immunohistochemical expression. International Journal of Cancer 74 171-174.
6. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J & Nilsson S 1998 Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Molecular Pharmacology 54 105-112.
7. Beekman JM, Allan GF, Tsai SY, Tsai MJ & Omalley BW 1993 Transcriptional activation by the estrogen-receptor requires a conformational change in the ligand-binding domain. Molecular Endocrinology 1 1266-1274.
8. Berns EM, Foekens JA, van Staveren IL, van Putten WL, de Koning HY, Portengen H & Klijn JG 1995 Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159 11-18.
9. Berry M, Metzger D & Chambon P 1990 Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO Journal 9 2811-2818.
10. Bieche I, Olivi M, Nogues C, Vidaud M & Lidereau R 2002 Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. British Journal of Cancer 86 580-586.
11. Blackwood EM & Eisenman RN 1991 Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251 1211-1217.
12. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA & Sutherland RL 1993 Expression and amplification of cyclin genes in human breast cancer. Oncogene 8 2127-2133.
13. Bukholm IR, Bukholm G & Nesland JM 2001 Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. International Journal of Cancer 93 283-287.
14. Bunone G, Briand PA, Miksicek RJ & Picard D 1996 Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO Journal 15 2174-2183.
15. Caffo O, Doglioni C, Veronese S, Bonzanini M, Marchetti A, Buttitta F, Fina P, Leek R, Morelli L, Palma PD, Harris AL & Barbareschi M 1996 Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clinical Cancer Research 2 1591-1599.
16. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S & Nakshatri H 2001 Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor a: a new model for anti-estrogen resistance. Journal of Biological Chemistry 276 9817-9824.
17. Carroll JS, Swarbrick A, Musgrove EA & Sutherland RL 2002 Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Research 62 3126-3131.
18. Chu I, Blackwell K, Chen S & Slingerland J 2005 The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Research 65 18-25.
19. Clarke RB, Laidlaw IJ, Jones LJ, Howell A & Anderson E 1993 Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. British Journal of Cancer 67 606-611.
20. Colditz GA 1998 Relationship between estrogen levels use of hormone replacement therapy, and breast cancer. Journal of the National Cancer Institute 90 814-823.
21. Coutts AS & Murphy LC 1998 Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Research 58 4071-4074.
22. Cuny M, Kramar A, Courjal F, Johannsdottir V, Iacopetta B, Fontaine H, Grenier J, Culine S & Theillet C 2000 Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Research 60 1077-1083.
23. Curtis SW, Washburn T, Sewall C, DiAugustine R, Lindzey J, Couse JF & Korach KS 1996 Physiological coupling of growth factor and steroid receptor signaling pathways: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. PNAS 93 12626-12630.
24. Dang CV 1999 c-Myc target genes involved in cell growth, apoptosis and metabolism. Molecular and Cellular Biology 19 1-11.
25. Deming SL, Nass SJ, Dickson RB & Trock BJ 2000 C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. British Journal of Cancer 83 1688-1695.
26. Dhillon NK & Mudryj M 2002 Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest. Oncogene 21 4626-4634.
27. Dickson C, Fantl V, Gillett C, Brookes S, Bartek J, Smith R, Fisher C, Barnes D & Peters G 1995 Amplification of chromosome band 11q13 and a role for cyclin Dl in human breast cancer. Cancer Letters 90 43-50.
28. Diehl JA, Xheng M, Roussel M & Sherr CJ 1998 Glycogen synthase kinase-3b regulates cyclin D1 proteolysis and subcellular localization. Genes and Development 12 3499-3511.
29. Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N & Smith I 2001 HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Research 61 8452-8458.
30. Dubik D & Shiu RP 1992 Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7 1587-1594.
31. Dubik D & Shiu RP 1988 Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. Journal of Biological Chemistry 263 12705-12708.
32. Dubik D, Dembinski TC & Shiu RP 1987 Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Research 47 6517-6521.
33. Dufourny B, Alblas J, van Teeffelen HAAM, van Schaik FMA, van der Burg B, Steenbergh PH & Sussenbach JS 1997 Mitogenic signalling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. Journal of Biological Chemistry 272 31163-31171.
34. Foster JS & Wimalasena J 1996 Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Molecular Endocrinology 10 488-498.
35. Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE & Nicholson RI 2003 The anti-epidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144 5105-5117.
36. Gohring UJ, Bersch A, Becker M, Neuhaus W & Schondorf T 2001 p21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer. Journal of Clinical Pathology 54 866-870.
37. Hamelers IHL, van Schaik FMA, Sipkema J, Sussenbach JS & Steenbergh PH 2002 Insulin-like growth factor I triggers nuclear accumulation of cyclin D1 in MCF7S breast cancer cells. Journal of Biological Chemistry 277 47645-47652.
38. Han S, Park K, Bae BN, Kim KH, Kim HJ, Kim YD & Kim HY 2003a Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer. Oncology Reports 10 141-144.
39. Han S, Park K, Bae BN, Kim KH, Kim HJ, Kim YD & Kim HY 20036 Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer. Journal of Surgical Oncology 83 241-247.
40. Hanson KD, Shichiri M, Follansbee MR & Sedivy JM 1994 Effects of c-myc expression on cell cycle progression. Molecular and Cellular Biology 14 5748-5755.
41. Heikkila R, Schwab G, Wickstrom E, Loke SL, Pluznik DH, Watt R & Neckers LM 1987 A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. Nature 328 445-449.
42. Hewitt SC, Harrell JC & Korach KS 2005 Lessons in estrogen biology from knockout and transgenic animals. Annual Review of Physiology 67 285-308.
43. Hodges LC, Cook JD, Lobenhofer EK, Li L, Bennett L, Bushel PR, Aldaz CM, Afshari CA & Walker CL 2003 Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Molecular Cancer Research 1 300-311.
44. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS & Group AT 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 60-62.
45. Huang Y, Ray S, Reed JC, Ibrado AM, Tang C, Nawabi A & Bhalla K 1997 Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Research and Treatment 42 73-81.
46. Hui R, Finney GL, Carroll JS, Lee CSL, Musgrove EA & Sutherland RL 2002 Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T47D breast cancer cells. Cancer Research 62 6916-6923.
47. Ignar-Trowbridge DM, Pimentel M, Parker MG, McLachlan JA & Korach KS 1996 Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology 137 1735-1744.
48. Jansen-Durr P, Meichle A, Steiner P, Pagano M, Finke K, Botz J, Wessbecher J, Draetta G & Eilers M 1993 Differential modulation of cyclin gene expression by MYC. PNAS 90 3685-3689.
49. Jeng M-H, Shupnik MA, Bender TP, Westin EH, Bandyopadhyay D, Kumar R, Masamura S & Santen RJ 1998 Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 139 4164-4174.
50. Jeng MH, Yue W, Eischeid A, Wang JP & Santen RJ 2000 Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells. Breast Cancer Research and Treatment 62 167-175.
51. Jordan NJ, Gee JMW, Barrow D, Wakeling AE & Nicholson DW 2004 Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Research and Treatment 87 167-180.
52. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D & Chambon P 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270 1491-1494.
53. Kenny FS, Hui R, Musgrove EA, Gee JMW, Blamey RW, Nicholson RI, Sutherland RL & Robertson JFR 1999 Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clinical Cancer Research 5 2069-2076.
54. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW & Bacus SS 2002 Cyclin E and survival in patients with breast cancer. New England Journal of Medicine 347 1566-1575.
55. Kilker RL, Hartl MW, Rutherford TM & Planas-Silva MD 2004 Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 92 63-71.
56. Kim HK, Park IA, Heo DS, Noh DY, Choe KJ, Bang YJ & Kim NK 2001 Cyclin E overexpression as an independent risk factor of visceral relapse in breast cancer. European Journal of Surgical Oncology 27 464-471.
57. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE & Nicholson RI 2003 Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144 1032-1044.
58. Kurokawa H, Lenferink AEG, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT & Arteaga CL 2000 Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Research 60 5887-5894.
59. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM & Webb P 2000 Estrogen receptor pathways to AP-1. Journal of Steroid Biochemistry and Molecular Biology 74 311-317.
60. Kyprianou N, English HF, Davidson NE & Isaacs JT 1991 Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Research 51 162-166.
61. Lai A, Sarcevic B, Prall OWJ & Sutherland RL 2001 Insulin/insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-cdk2 activation and cell cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21WAF1/CIP1. Journal of Biological Chemistry 276 25823-25833.
62. Lee A, Weng C, Jackson J & Yee D 1997 Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. Journal of Endocrinology 152 786-794.
63. Lobenhofer E, Huper G, Ihlehart J & Marks J 2000 Inhibition of mitogen-activated protein kinase and phosphotidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth and Differentiation 11 99-110.
64. 1 checkpoint. Molecular and Cellular Biology 16 6917-6925.
65. Martin MB, Franke TF, Stoica GE, Chambon P, Katzenellenbogen BS, Stoica BA, McLemore MS, Olivo SE & Stoica A 2000 A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 141 4503-4511.
66. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C & Dowsett M 2003 Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. Journal of Biological Chemistry 278 30458-30468.
67. Mawson A, Lai A, Carroll JS, Sergio CM, Mitchell CJ & Sarcevic B 2005 Estrogen and insulin/IGF-I cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. Molecular and Cellular Endocrinology 229 161-173.
68. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, Gee JM & Nicholson RI 2001 Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142 2776-2788.
69. McDonnell DP, Clemm DL, Hermann T, Goldman ME & Pike JW 1995 Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Molecular Endocrinology 9 659-669.
70. Miller DL, el-Ashry D, Cheville AL, Liu Y, McLeskey SW & Kern FG 1994 Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression. Cell Growth and Differentiation 5 1263-1274.
71. Mita MM, Mita A & Rowinsky EK 2003 Mammalian target of rapamycin: a new molecular target for breast cancer. Clinical Breast Cancer 4 126-137.
72. Mukherjee S & Conrad SE 2005 C-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. Journal of Biological Chemistry 280 17617-17625.
73. Musgrove EA, Hamilton JA, Lee CS, Sweeney KJ, Watts CK & Sutherland RL 1993 Growth factor steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Molecular and Cellular Biology 13 3577-3587.
74. Musgrove EA, Lee CS, Buckley MF & Sutherland RL 1994 Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. PNAS 91 8022-8026.
75. Musgrove EA, Hunter L-JK, Lee CSL, Swarbrick A, Hui R & Sutherland RL 2001 Cyclin Dl overexpression induces progestin resistance in T47D breast cancer cells despite p27KIP1 association with cyclin E-cdk2. Journal of Biological Chemistry 275 47675-47683.
76. Naidu R, Wahab NA, Yadav M & Kutty MK 2002 Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. International Journal of Molecular Medicine 9 189-196.
77. Nass SJ & Dickson RB 1997 Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Research and Treatment 44 1-22.
78. Nass SJ & Dickson RB 1998 Epidermal growth factor-dependent cell cycle progression is altered in mammary epithelial cells that overexpress c-myc. Clinical Cancer Research 4 1813-1822.
79. Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J, Pestell RG, Hinds PW, Dowdy SF, Brown M & Ewen ME 1997 Cyclin Dl stimulation of estrogen receptor transcriptional activity independent of cdk4. Molecular and Cellular Biology 17 5338-5347.
80. Neve RM, Sutterluty H, Pullen N, Lane HA, Daly JM, Krek W & Hynes NE 2000 Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene 19 1647-1656.
81. Nicholson RI, Hutcheson IR, Hiscox SE, Knowlden JM, Giles MG, Barrow D, Wakeling AE & Gee JM 2005 Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: The use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocrine-Related Cancer (In Press).
82. O'Hanlon DM, Kiely M, MacConmara M, Al-Azzawi R, Connolly Y, Jeffers M & Keane FB 2002 An immunohistochemical study of p21 and p53 expression in primary node-positive breast carcinoma. European Journal of Surgical Oncology 28 103-107.
83. Oster SK, Mao DYL, Kennedy J & Penn LZ 2003 Functional analysis of the N-terminal domain of the Myc oncoprotein. Oncogene 22 1998-2010.
84. Pellikainen MJ, Pekola TT, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ & Kosma VM 2003 p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis. Journal of Clinical Patholology 56 214-220.
85. Perez-Roger I, Soloman DL, Sewing A & Land H 1997 Myc activation of cyclin E/cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) binding to newly formed complexes. Oncogene 14 2373-2381.
86. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX & Slamon DJ 1995 HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10 2435-2446.
87. Planas-Silva MD & Weinberg RA 1997 Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Molecular and Cellular Biology 17 4059-4069.
88. Prall OWJ, Sarcevic B, Musgrove EA, Watts CK & Sutherland RL 1997 Estrogen-induced activation of cdk4 and cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-cdk2. Journal of Biological Chemistry 272 10882-10894.
89. Prall OWJ, Rogan EM, Musgrove EA, Watts CK & Sutherland RL 1998 c-Myc or cyclin D1 mimics estrogen effects on cyclin E-cdk2 activation and cell cycle reentry. Molecular and Cellular Biology 18 4499-4508.
90. Prall OWJ, Carroll JS & Sutherland RL 2001 A low abundance pool of nascent p21WAF/CIP1 is targeted by estrogen to activate cyclin E-cdk2. Journal of Biological Chemistry 276 45433-45442.
91. Robertson JFR, Gutteridge E, Cheung KL, Owers R, Koehler M, Hamilton L, Gee JM & Nicholson RI 2003 Gefitinib (ZD 1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a Phase II study. Proceedings for the American Society of Clinical Oncology 22 7.
92. Roux-Dosseto M & Martin PM 1989 A paradigm for oncogene complementation in human breast cancer. Research in Virology 140 571-591.
93. Rudolph B, Saffrich R, Zwicker J, Henglein B, Muller R, Ansorge W & Eilers M 1996 Activation of cyclin-dependent kinases by Myc mediates induction of cyclin A, but not apoptosis. EMBO Journal 15 3065-3076.
94. Rudolph P, Kuhling H, Aim P, Ferno M, Baldetorp B, Olsson H & Parwaresch R 2003 Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. International Journal of Cancer 105 674-680.
95. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH & Yue W 2002 The role of mitogen-activated protein (MAP) kinase in breast cancer. Journal of Steroid Biochemistry and Molecular Biology 80 239-256.
96. Schlotter CM, Vogt U, Bosse U, Mersch B & Wassmann K 2003C-myc not HER-2/neu can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Research 5 R30-R36.
97. Sears R, Lone G, DeGregori J & Nevins JR 1999 Ras enhances Myc protein stability. Molecular Cell 3 169-179.
98. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K & Nevins JR 2000 Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes and Development 14 2501-2514.
99. Seshadri R, Lee CS, Hui R, McCaul K, Horsfall DJ & Sutherland RL 1996 Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clinical Cancer Research 2 1177-1184.
100. Sivaraman VS, Wang H-Y, Nuovo GJ & Malbon CC 1997 Hyperexpression of mitogen-activated protein kinase in human breast cancer. Journal of Clinical Investigation 99 1478-1483.
101. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A & McGuire WL 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 177-182.
102. Span PN, Tjan-Heijnen VC, Manders P, Beex LV & Sweep CG 2003 Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 22 4898-4904.
103. Stendahl M, Kronblad A, Ryden L, Emdin S, Bengtsson NO & Landberg G 2004 Cyclin Dl overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. British Journal of Cancer 90 1942-1948.
104. Stoica GE, Franke TF, Moroni M, Mueller S, Morgan E, Iann MC, Winder AD, Reiter R, Wellstein A, Martin MB & Stoica A 2003 Effect of estradiol on estrogen receptor-α gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene 22 7998-8011.
105. Taylor RE, Powles TJ, Humphreys J, Bettelheim R, Dowsett M, Casey AJ, Neville AM & Coombes RC 1982 Effects of endocrine therapy on steroid-receptor content of breast cancer. British Journal of Cancer 45 80-85.
106. Teixeira C, Reed JC & Pratt MA 1995 Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Research 55 3902-3907.
107. Thiantanawat A, Long BJ & Brodie AM 2003 Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Research 63 8037-8050.
108. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW & McDonnell DP 1994 Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Molecular Endocrinology 8 21-30.
109. Utsumi T, Yoshimura N, Maruta M, Takeuchi S, Ando J, Mizoguchi Y & Harada N 2000 Correlation of cyclin D1 MRNA levels with clinico-pathological parameters and clinical outcome in human breast carcinomas. International Journal of Cancer 89 39-43.
110. Venditti M, Iwasiow B, Orr FW & Shiu RP 2002 C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells. International Journal of Cancer 99 35-42.
111. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A & Schmidt EV 1994 Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369 669-671.
112. Watson PH, Pon RT & Shiu RP 1991 Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Research 51 3996-4000.
113. Watts CK, Sweeney KJ, Warlters A, Musgrove EA & Sutherland RL 1994 Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells. Breast Cancer Research and Treatment 31 95-105.
114. Watts CK, Brady A, Sarcevic B, deFazio A, Musgrove EA & Sutherland RL 1995 Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Molecular Endocrinology 9 1804-1813.
115. Weigel NL & Zhang Y 1998 Ligand-independent activation of steroid hormone receptors. Journal of Molecular Medicine 76 469-479.
116. West MJ, Stoneley M & Willis AE 1998 Translational induction of the c-myc oncogene via activation of the FRAP/TOR signaling pathway. Oncogene 17 769-780.
117. Wilcken NR, Prall OW, Musgrove EA & Sutherland RL 1997 Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clinical Cancer Research 3 849-854.
118. Winters ZE, Leek RD, Bradburn MJ, Norbury CJ & Harris AL 2003 Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Research 5 R242-R249.
119. Xia W, Chen JS, Zhou X, Sun PR, Lee DF, Liao Y, Zhou BP & Hung MC 2004 Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clinical Cancer Research 10 3815-3824.
120. Yarden RI, Wilson M & Chrysogelos SA 2001 Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. Journal of Cellular Biochemistry 36 232-246.
121. Zafonte BT, Hulit J, Amanatullah DF, Albanese C, Wang C, Rosen E, Reutens A, Sparano JA, Lisanti MP & Pestell RG 2000 Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle. Frontiers in Bioscience 5 D938-D961.
122. Zwijsen RML, Wientjens E, Klompmaker R, van der Sman J, Bernards R & Michalides RJAM 1997 CDK-independent activation of estrogen receptor by cyclin D1. Cell 88 405-415.